Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2005

01-06-2005 | Leading Article

Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders

Authors: Dr Malcolm Peet, Caroline Stokes

Published in: Drugs | Issue 8/2005

Login to get access

Abstract

The importance of omega-3 fatty acids for physical health is now well recognised and there is increasing evidence that omega-3 fatty acids may also be important to mental health. The two main omega-3 fatty acids in fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have important biological functions in the CNS. DHA is a major structural component of neuronal membranes, and changing the fatty acid composition of neuronal membranes leads to functional changes in the activity of receptors and other proteins embedded in the membrane phospholipid. EPA has important physiological functions that can affect neuronal activity. Epidemiological studies indicate an association between depression and low dietary intake of omega-3 fatty acids, and biochemical studies have shown reduced levels of omega-3 fatty acids in red blood cell membranes in both depressive and schizophrenic patients.
Five of six double-blind, placebo-controlled trials in schizophrenia, and four of six such trials in depression, have reported therapeutic benefit from omega-3 fatty acids in either the primary or secondary statistical analysis, particularly when EPA is added on to existing psychotropic medication. Individual clinical trials have suggested benefits of EPA treatment in borderline personality disorder and of combined omega-3 and omega-6 fatty acid treatment for attention-deficit hyperactivity disorder. The evidence to date supports the adjunctive use of omega-3 fatty acids in the management of treatment unresponsive depression and schizophrenia. As these conditions are associated with increased risk of coronary heart disease and diabetes mellitus, omega-3 fatty acids should also benefit the physical state of these patients. However, as the clinical research evidence is preliminary, large, and definitive randomised controlled trials similar to those required for the licensing of any new pharmacological treatment are needed.
Literature
1.
Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999; 70 Suppl. 3: 560S-9S
2.
Hu FB, Willet WC. Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569–78PubMedCrossRef
3.
Cleland LG, James MJ, Proudman SM. The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003; 63(9): 845–53PubMedCrossRef
4.
Crawford MA, Bloom M, Cunnane S, et al. Docosahexaenoic acid and cerebral evolution. World Rev Nutr Diet 2001; 88: 6–17PubMedCrossRef
5.
Uauy R, Peirano P, Hoffman D, et al. Role of essential fatty acids in the function of the developing nervous system. Lipids 1996; 31 Suppl.: S167–76PubMedCrossRef
6.
Wainwright PE. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002; 61: 61–9PubMedCrossRef
7.
Salem Jr N, Litman B, Kim HY, et al. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945–59PubMedCrossRef
8.
Burdge G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004; 7: 137–44PubMedCrossRef
9.
Horrobin DF, Manku MS, Hillman H, et al. Fatty acid levels in the brains of schizophrenic and normal controls. Biol Psychiatry 1991; 30: 795–805PubMedCrossRef
10.
Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8–21PubMedCrossRef
11.
Rudin DO. The major psychosis and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981; 16: 837–50PubMed
12.
Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenia patients. J Psychiatr Res 1995; 29: 227–32PubMedCrossRef
13.
Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II: fatty acid composition. Schizophr Res 1994; 13: 217–26
14.
Glen AL, Glen EM, Horrobin DF, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53–61PubMedCrossRef
15.
16.
Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003; 160: 2222–7PubMedCrossRef
17.
Hibbeln JR. Seafood consumption and homicide mortality: a cross-national ecological analysis.World Rev Nutr Diet 2001; 88: 41–6PubMedCrossRef
18.
Hibbeln JR. Seafood consumption, the DHA content of mother’s milk, and prevalence rates of postpartum depression: a cross-national ecological analysis. J Affect Disord 2002; 69: 15–29PubMedCrossRef
19.
Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243–51PubMedCrossRef
20.
Emsley R, Myburgh C, Ousthuizen P, et al. Randomised, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596–8PubMedCrossRef
21.
Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7–18PubMedCrossRef
22.
Fenton WS, Dickenson FM, Borrow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 258: 2071–4CrossRef
23.
Berger GE, Proffitt T, Wood S, et al. Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: a double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients [abstract]. Int J Neuropsychopharmacol 2004; 8 Suppl. 1: S422
24.
Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477–9PubMedCrossRef
25.
Peet M, Horrobin DF. A close-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913–9PubMedCrossRef
26.
Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder; a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13: 267–71PubMedCrossRef
27.
Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996–8PubMedCrossRef
28.
Edwards RH. A study of omega-3 polyunsaturated fatty acids in depression [PhD thesis]. Sheffield: University of Sheffield, 2002
29.
Keck PE, McElroy SL, Freeman MP, et al. Randomised, placebo-controlled trial of eicosapentaenoic acid in bipolar depression [abstract]. Bipolar Disord 2003; 5 Suppl. 1: 58
30.
Frangou S, Lewis M. Efficacy of eicosapentaenoic acid in bipolar depression: a double-blind randomised trial [abstract]. Bipolar Disord 2002; 4 Suppl. 1: 123
31.
Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407–12PubMedCrossRef
32.
Keck PE, Freeman MP, McElroy SL, et al. A double-blind, placebo-controlled trial of eicosapentaenoic acid in rapid cycling bipolar disorder [abstract]. Bipolar Disord 2002; 4 Suppl. 1: 26–7CrossRef
33.
Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167–9PubMedCrossRef
34.
Hamazaki T, Sawazaki S, Itomura M, et al. The effect of docosahexaenoic acid on aggression in young adults: a placebo-controlled double-blind study. J Clin Invest 1996; 97: 1129–33PubMedCrossRef
35.
Hamazaki T, Thienprasert A, Kheovichaik K, et al. The effects of docosahexaenoic acid on aggression in elderly Thai subjects: a placebo-controlled double-blind study. Nutr Neurosci 2002; 5: 37–41PubMedCrossRef
36.
Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention deficit hyperactivity disorder: a placebo controlled double-blind study. Eur J Clin Nutr 2004; 58: 467–73PubMedCrossRef
37.
Voigt RG, Llorente AM, Jensen CL, et al. A randomised, double blind, placebo controlled trail of docosahexaenoic acid supplementation in children with attention deficit hyperactivity disorder. J Pediatr 2001; 139: 189–96PubMedCrossRef
38.
Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity and other disruptive behaviours. Lipids 2003; 38: 1007–21PubMedCrossRef
39.
Richardson AJ, Puri BK. A randomised, double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 233–9PubMedCrossRef
40.
Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 2004; 38: 323–5PubMedCrossRef
41.
Morris MC, Evans DA, Bienas JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60: 940–6PubMedCrossRef
42.
Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat and risk of dementia: a cohort study. BMJ 2002; 325: 932–3PubMedCrossRef
43.
Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br J Psychiatry 2004; 184: 404–8PubMedCrossRef
44.
Tanskanen A, Hibbeln JR, Tuomilehto J, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001; 52(4): 529–31PubMedCrossRef
45.
Silver KM, Scott KM. Fish consumption and self-reported physical and mental health status. Public Health Nutr 2002; 5: 427–31
46.
Hakkarainen R, Partonen T, Haukka J, et al. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 2004; 161: 567–9PubMedCrossRef
47.
Timonen M, Horrobin D, Jokelainen J, et al. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 2004; 82: 447–52PubMed
48.
Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149–55PubMedCrossRef
49.
Peet M, Shah S, Selvam K, et al. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J Biol Psychiatry 2004; 5: 92–9PubMedCrossRef
50.
Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78: 587–91PubMedCrossRef
51.
Mellor JE, Laugharne JDR, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 1996; 11: 39–46CrossRef
52.
Stokes C, Peet M. Dietary intake of sugar and polyunsaturated fatty acids predicts the severity of schizophrenic symptoms. Nutr Neurosci 2004; 7: 247–9PubMedCrossRef
53.
54.
Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome-proliferator activated receptors. Mol Cell 1999; 3: 397–403PubMedCrossRef
55.
Kitajka K, Puskas LG, Zvara A, et al. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci U S A 2002; 99: 19–24CrossRef
56.
Bennett CN, Horrobin DF. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 47–59PubMedCrossRef
57.
Seung Kim HF, Weeber EJ, Sweatt JD, et al. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry 2001; 6: 246–8PubMedCrossRef
58.
Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines and immune responses. Int Rev Neurobiol 2002; 52: 275–302PubMedCrossRef
59.
Muller N, Riedel M, Schoppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029–34PubMedCrossRef
60.
Mehta D, editor. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2004
61.
Damico KE, Stoll AL, Marangell LB, et al. How blind is double-blind? A study of fish oil versus placebo. Prostaglandins Leukot Essent Fatty Acids 2002; 666: 393–5CrossRef
62.
US Food and Drug Administration. Substances affirmed as generally recognised as safe: Menhaden oil. Fed Regist 1997; 62: 30751–7
63.
Mochida Pharmaceutical Co., Ltd. Epadel capsules 300 data sheet. Tokyo: Mochida Pharmaceutical Co., Ltd, 1998
64.
Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 221–7PubMedCrossRef
65.
Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–7PubMedCrossRef
66.
Eritsland J, Arnesen H, Seljeflot I, et al. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary heart disease. Blood Coagul Fibrinolysis 1995; 6: 17–22PubMedCrossRef
67.
Farmer A, Montori V, Dinneen S, et al. Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2001; (3): CD003205
68.
Friedberg CE, Janssen MJ, Heine RJ, et al. Fish oil and glycemic control in diabetes. Diabetes Care 1998; 21: 494–500PubMedCrossRef
69.
Scientific Advisory Committee on Nutrition. Advice on fish consumption: benefits and risks. London: The Stationary Office, 2004
70.
Peet M, Glen I, Horrobin DF. Phospholipid spectrum disorders in psychiatry and neurology. Carnforth, Lancashire: Marius Press, 2003
71.
Voutilainen S, Lakka TA, Porkkala-Sarataho E, et al. Low serum folate concentrations are associated with an excess incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr 2000; 54: 424–8PubMedCrossRef
72.
Reynolds EH. Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry 2002; 72: 567–71PubMedCrossRef
73.
Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137–46PubMedCrossRef
Metadata
Title
Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders
Authors
Dr Malcolm Peet
Caroline Stokes
Publication date
01-06-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565080-00002

Other articles of this Issue 8/2005

Drugs 8/2005 Go to the issue

Review Article

First-Episode Schizophrenia

Review Article

Angiotensin Antagonism in Coronary Artery Disease

Adis Drug Evaluation

Recombinant Factor VIIa (Eptacog Alfa)

Review Article

Bacterial Meningitis in Children

Current Opinion

Enteric-Coated Mycophenolate Sodium

Therapy in Practice

The Role of Topical Retinoids in the Treatment of Photoaging